Drug Trial Radar · NCT01235442
Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Aug 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
592
Actual
Start
Sep 2010
Primary completion
Oct 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- Wyeth is now a wholly owned subsidiary of Pfizer
- First posted
- Nov 5, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary hypothesis of this trial is that the addition of short courses of clobetasol propionate foam to etanercept monotherapy in subjects with moderate to severe plaque psoriasis will yield greater efficacy compared with etanercept monotherapy, as measured by PASI 75 at Week 12.
Conditions
- Psoriasis
Interventions
1=EtanerceptDrug
50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
2=Clobetasol propionate foamDrug
0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
Primary outcomes
What the sponsor says the trial is designed to measure.
- PASI 75 at Week 12Time frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.